BHARE Foundation

Spring, 2018

BHARE Foundation supporters,

Your generosity in 2017 was overwhelming. The Microbiota Transfer Therapy (MTT) research at Arizona State University is almost 100% funded.   Our commitment to the study is $128,000.  We now have $110,000, and with your help, we will raise the final $18,000.  Phase II of the study has already begun.  Our funds are not needed until the end of the study when the metabolomics will be measured prior to, and after giving, the MTT.  Completing the study and publishing the results may take 18 months or longer.

In May 2017, there was a small, yet highly interesting study.  “Low-dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial”.  Five male subjects with autism aged 5-14, were administered a single intravenous infusion of a drug called suramin.  Five age matched controls were given placebo infusions.  All children in the suramin group showed improvements in language, social interaction, and a decrease in restrictive or repetitive behaviors.  Unfortunately, all subjects returned to baseline within 6 weeks of the infusion.  The lead investigator, Dr. Robert K. Naviaux stated, “Suramin works by inhibiting the signaling function of adenosine triphosphate, which is produced by the cellular mitochondria and released from cells to signal danger.  Suramin signals that ‘the cellular war is over, the danger has passed and cells can return to ‘peacetime’ jobs like normal neurodevelopment, growth and healing.”  I would summarize by saying that people with ASD are trapped in the “fight or flight” phase and that suramin brings them back to the “rest and digest” or “relaxation” stage.  This is a unique theory on why autism occurs, and one that needs to be explored.  Dr. Naviaux further states, “Metabolism is the language that the brain, gut and immune system use to communicate.  These systems are linked. You can’t change one without changing the others.”

Dr. Naviaux’s team is ready to begin phase II.  There will be a larger group of subjects as well as more than one infusion given over several months.  Funding for a large portion of the study seems to be in place.  Similar to the MTT study by Dr. Adams, Dr. Naviaux would also like to measure the metabolomics to discover what exactly changed, and therefore determine why the treatment works.  The BHARE Foundation has received a proposal to fund that portion of his work.  He is requesting $75,000.  Samples can be collected and held until we have the funds raised.  While we are currently committed to funding the MTT study, I would also like to pledge our support to this study as well.  To view    the first study and other publications regarding this work, go to bhare.org.

Lastly, I am hopeful in the near future, laws will allow marijuana to be studied for a treatment for autism.  Currently that is not the case in the US.  I have seen firsthand a significant improvement with my son sleeping through the night, as well as a tremendous reduction in the number of seizures.  It would be ideal to have funds available when the laws change so we can be at the cutting edge of that type of research.

Please send a check or donate now via PayPal.   Ask your employer if they have a matching grant program.  We are making progress and with your continued support, we will help the many that desperately need it.

Thank you,

Bram Hornstein
The BHARE Foundation


First Steps Toward a Real Treatment for Autism.

Published in January 2017

The BHARE Foundation is pleased to note that they provided funding for basic scientific research to Profs. Adams and Krajmalnik-Brown, and that basic research provided critical data that helped justify the need for FMT and helped win FDA approval for the clinical trial.

Read the full study here: http://microbiomejournal.biomedcentral.com/articles/10.1186/s40168-016-0225-7

 


Folinic Acid Study

With your support, BHARE has been able to fund another positive study that was published this year. Please take a look at the tremendous effect you are creating by helping us fund research.

Folinic Acid Study